Patent intelligence · US
US 12403141
Deuterated MK2 pathway inhibitors and methods of using the same
Deuterated MK2 pathway inhibitors and methods of using the same
Patent details — US 12403141
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 2, 2025
- Expiration
- Aug 28, 2045
- Applicant
- Aclaris Therapeutics, Inc.
- Claims
- 7
- CPC classes
- A61K, A61K31/506, A61K45/06, A61P
Quick answer
US 12403141 (Deuterated MK2 pathway inhibitors and methods of using the same) is held by Aclaris Therapeutics, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aclaris Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K31/506, A61K45/06, A61P, A61P35/00, A61P37/02
More from Aclaris Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12370195
Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
granted -
US 12297203
Pyrrolopyrimidine ITK inhibitors
granted -
US 12281111
Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
granted -
US 11844801
Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
granted -
US 11820775
Pyrrolopyrimidine ITK inhibitors
granted -
US 11739086
Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
granted -
US 10981906
Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
granted
Frequently asked questions
What is US patent 12403141?
US 12403141 (Deuterated MK2 pathway inhibitors and methods of using the same) is held by Aclaris Therapeutics, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12403141?
Aclaris Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does US 12403141 expire?
Our index shows an expiration date of Aug 28, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.